Pharmaceutical giant says its vaccine only "may be" effective in reducing "severe disease and hospitalization," and falls short of confirming protection from infection.
As of the conclusion of the prior year, the firm, with its linked enterprises holding assets in the U.S., declared outstanding liabilities amounting to $335 billion.
